Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
(NASDAQ: RVMD) Delayed: 153.87 +4.64 (3.11%)
Previous Close $149.23    52 Week High $ 
Open $150.40    52 Week Low $ 
Day High $154.74    P/E N/A 
Day Low $149.67    EPS $ 
Volume 1,581,059